Quant Biomarkers
Basel, Switzerland
Recent progresses in Cardio-Kidney-Metabolic diseases, which affect >40% world population, make Pharma investing heavily on new CKM candidates. But they lack tools to identify/stratify early kidney injury cases and lack surrogate markers to monitor nephroprotection. To help Pharma unlock the big market, Quant Biomarkers is developing the RenoRisk biomarker panel that originate from and can detect the earliest pathology of kidney injury, enabling a 3-6yr earlier reversible treatment time window.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2021
- Website
- quantbio.swiss/
Only accessible to MedStartr community members.
Join nowWhat do you think of Quant Biomarkers?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now